Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)Seeking Alpha • 4h
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDAGlobeNewsWire • 11h
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • Thursday
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ETGlobeNewsWire • 10/08/26
AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowZacks Investment Research • 10/06/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIOPRNewsWire • 08/13/26
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over YearZacks Investment Research • 07/31/26
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 07/30/26
Agios Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 07/30/26
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/23/26
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD ProgramZacks Investment Research • 07/22/26
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This WeekThe Motley Fool • 07/10/26
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock UpZacks Investment Research • 07/08/26
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?Zacks Investment Research • 07/08/26
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)The Motley Fool • 07/07/26